stock takes

We’re set to receive shares in Danaher’s separated water business. Here’s our plan for the new stock
Danaher (DHR) is days away from shedding its environmental-and-applied solutions segment, and the Club holding’s ability to deliver returns for shareholders appears stronger than ever. Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that’s in the business of water quality. We see underappreciated value in […]
Read More
Health care has had a tough year. Where we stand on our 5 stocks in the sector
There’s Eli Lilly (LLY), and then there’s everybody else. That’s a simple way to describe the performance of the Club’s health-care holdings so far this year, in what’s been a challenging period for the industry overall. Of the 11 market sectors year to date, health care is the fourth worth-worst performer, falling 4%, followed by […]
Read More
Here are the risks to alcohol and food stocks from Ozempic-like weight loss drugs
The rise of new anti-obesity medications could result in less alcohol consumption, impacting Club name Constellation Brands (STZ). The risk already seems to be playing out in food stocks with exposure to snacks and junk food. However, if necessary, the Mexican beer powerhouse behind Corona, Modelo and Pacifico could take action to mitigate any demand […]
Read More
This health-care stock is set to complete another spin-off. Here’s what it means for our position in the stock
Medical equipment giant Danaher (DHR) will officially spin off its environmental-and-applied solutions segment later this month, and our plan is to remain invested in the soon-to-be standalone company, known as Veralto, which will trade under the ticker symbol VLTO. That expectation was reinforced Wednesday when Veralto management delivered a presentation for investors and Wall Street […]
Read More
Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
This biotech name is one of Jim Cramer’s favorite stocks and he thinks it can go even higher
Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free. CNBC’s Jim Cramer said on “Squawk on the Street” that Regeneron is […]
Read More
Here are the 5 price-target changes and 4 trades we made during this busy earnings week
In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. Monday The week began with our decision to exit […]
Read More
Here’s what Jim Cramer thinks about J&J stock after a pivotal talc case verdict
A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J’s proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was “too […]
Read More
Cramer says snap up this leading medtech stock — wishes he could buy shares too
GE Healthcare (GEHC) shares are sliding Thursday, giving Club members an opportunity to invest in the medical-technology company at an increasingly attractive valuation. The sellers Thursday are making a mistake, and we would capitalize on their misjudgment if not for restrictions that prevent us from trading the stock. Shares of GE Healthcare fell around 3% […]
Read More